Clinical Trial Update: A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial is evaluating the safety and preliminary efficacy of QT-019C, a universal allogeneic CAR-T therapy targeting CD19 and BCMA, in pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• QT-019C CAR-T therapy (QT-019C CAR-T)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Immune Thrombocytopenia (ITP) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING